OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial	140
CAR T-cell therapy comes of age: Introductory editorial for the special issue	60
Clinical applications of circulating tumor DNA in Hodgkin lymphoma	40
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies	33
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia	31
Evolving Insights into Mitochondrial Presence in RBC in Sickle Cell Disease: Red Blood Cell and Reticulocyte Pathophysiology, Therapeutic Strategies, and Future Directions	29
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	28
Updates on current and future research in acute myeloid leukemia	27
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19	22
How to set up a clinical research center in Brazil, as an example of a middle-income country	21
Epidemiology and etiology of diffuse large B-cell lymphoma	20
Somatic mutations in “benign” blood diseases	19
Lessons learned from the Eµ-TCL1 mouse model of CLL	19
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence	18
Antibody and immunotherapy in diffuse large B-cell lymphoma	17
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services	17
More disease-modifying therapies for sickle cell disease: Are small molecules and drug repurposing the way forward?	16
TET2 mutation as prototypic clonal hematopoiesis lesion	16
The role of viruses in HIV-associated lymphomas	15
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future	15
MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms	15
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?	14
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors	13
The molecular map of CLL and Richter's syndrome	13
T-cell engaging antibodies for B-cell lymphomas	13

Vaccinations in patients with chronic lymphocytic leukemia	12
Developing MRD as an early endpoint for accelerated approval in CLL	12
Roadmap for developing MRD as an early endpoint for drug approval in lymphoma	12
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics	12
outside front cover, PMS 8883 metallic AND 4/C	11
Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?	11
Clonal hematopoiesis	11
Cellular and immunotherapies for myelodysplastic syndromes	11
Challenges and opportunities of CAR T-cell therapies for CLL	10
outside front cover, PMS 8883 metallic AND 4/C	10
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead	10
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients	10
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	9
Harnessing single-domain antibodies for CAR-T and bispecific antibody development	9
The biology of classical Hodgkin lymphoma	9
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	9
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations	9
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy	9
Somatic mutations in acquired pure red cell aplasia	8
The pediatric approach to Hodgkin lymphoma	8
Menin inhibition for the treatment of acute leukemia	8
Engineering the Next Generation of Antibody Therapeutics in Hematology	8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS	8
Blood-based MRD testing in multiple myeloma: Update on mass spectrometry methods for detecting the monoclonal immunoglobulin	7
Somatic compensation of inherited bone marrow failure	7
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology	7
Clinical applications of circulating tumor DNA in central nervous system lymphoma	7
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome	7
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia	7
DLBCL arising from indolent lymphomas: How are they different?	7
Understanding MDS stem cells: Advances and limitations	7
The crossroads of cancer therapies and clonal hematopoiesis	7
MRD as an early endpoint in myeloma and other hematologic malignancies: Implication for ongoing and future study designs	7
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials	7
Measurable residual disease after CAR T-cell therapy	6
Clonal hematopoiesis in telomere biology disorders	6
Diagnosis and management of hematologic malignancies in the context of telomere biology disorders	6
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease	6
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters	6
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies	6
miRNA Biology in Chronic Lymphocytic Leukemia	6
outside front cover, PMS 8883 metallic AND 4/C	6
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	5
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	5
Clonal hematopoiesis in the setting of hematopoietic cell transplantation	5
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management	5
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	5
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	5
License for a CAR T: Examining patient eligibility	5
outside front cover, PMS 8883 metallic AND 4/C	5

Updates on the biology of chronic lymphocytic leukemia: introductory editorial	5
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	5
AML diagnostics in the 21st century: Use of AI	4
Special edition of the Seminars in Hematology series on Global Hematology Care	4
Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma	4
table of contents (2 pages)	4
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications	4
RNA splicing as a therapeutic target in myelodysplastic syndromes	4
Role of the tumor microenvironment in CLL pathogenesis	4
Genetic aspects of telomere biology disorders	4
Bone marrow failure in telomere biology disorders: Current understanding and the emerging landscape of non-transplant therapies	4
Inflammation in myelodysplastic syndrome pathogenesis	4
The case for prioritizing malignant hematology services in low- and middle-income countries	4
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	4
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	4
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers	3
The Paradox of HbSC disease - Not so benign after all	3
Special issue on circulating tumor DNA: Introductory editorial	3
Resolving leukemic stem cell heterogeneity and plasticity with single-cell multiomics	3
Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories	3
Targeted immunoPET imaging of multiple myeloma	3
outside front cover, PMS 8883 metallic AND 4/C	3
Tuning CAR T-cell therapies for efficacy and reduced toxicity	3
Applications of virus-specific T cell therapies post-BMT	3
The Management of older patients with Hodgkin lymphoma: implications of S1826	3
The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies	3
outside front cover, PMS 8883 metallic AND 4/C	3
BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape	3
Rare somatic manifestations of telomere biology disorders	3
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?	3
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL	3
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes	3
Solid malignancies in telomere biology disorders	3
masthead	3
Minimal residual disease testing in hematologic malignancies: From early endpoint to precision clinical decision making	3